Skip to content

Study · Animal study (in vivo) · cynomolgus monkey · 2018

16 results

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.

Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA19 Dec 2017Cited by 56 (Europe PMC)

PMID29260289 (opens in a new tab)PMCIDPMC5834552 (opens in a new tab)DOI10.1007/s00198-017-4323-6 (opens in a new tab)PepBankPUB-29260289
Read at sourcePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased serum P1NP.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased a bone formation marker compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum P1NP
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration to OVX cynos led to increased bone formation parameters, including serum P1NP and endocortical bone formation rate.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased endocortical bone formation rate.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased bone formation at the inner cortex compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseEndocortical bone formation rate
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration to OVX cynos led to increased bone formation parameters, including serum P1NP and endocortical bone formation rate.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In ovariectomized monkeys, abaloparatide did not influence serum calcium.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not change blood calcium compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerum calcium
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration did not influence serum calcium levels, bone resorption markers, cortical porosity, or eroded surfaces.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide did not influence bone resorption markers.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not change bone breakdown markers compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone resorption markers
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration did not influence serum calcium levels, bone resorption markers, cortical porosity, or eroded surfaces.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide did not influence cortical porosity.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not change outer bone porosity compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeCortical porosity
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration did not influence serum calcium levels, bone resorption markers, cortical porosity, or eroded surfaces.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide did not influence eroded bone surfaces.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not change eroded bone surfaces compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeEroded surfaces
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration did not influence serum calcium levels, bone resorption markers, cortical porosity, or eroded surfaces.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased whole-body bone mass.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased total bone mass compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseWhole-body bone mass
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide increased bone mass at the whole body, lumbar spine, tibial diaphysis, femoral neck, and femoral trochanter.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased lumbar spine bone mass.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased spinal bone mass compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine bone mass
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide increased bone mass at the whole body, lumbar spine, tibial diaphysis, femoral neck, and femoral trochanter.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased tibial diaphysis bone mass.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased shinbone shaft mass compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTibial diaphysis bone mass
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide increased bone mass at the whole body, lumbar spine, tibial diaphysis, femoral neck, and femoral trochanter.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased femoral neck bone mass.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased femoral neck bone mass compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck bone mass
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide increased bone mass at the whole body, lumbar spine, tibial diaphysis, femoral neck, and femoral trochanter.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide increased femoral trochanter bone mass.

    In plain wordsIn monkeys with removed ovaries, abaloparatide increased bone mass near the upper femur compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral trochanter bone mass
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide increased bone mass at the whole body, lumbar spine, tibial diaphysis, femoral neck, and femoral trochanter.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized monkeys, abaloparatide was associated with greater lumbar vertebral strength.

    In plain wordsIn monkeys with removed ovaries, abaloparatide was linked to stronger spinal bones compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar vertebral strength
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration was associated with greater lumbar vertebral strength, and had no adverse effects on bone mass-strength relationships for the vertebrae, femoral neck, femoral diaphysis, or humeral cortical beams.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  13. 13AnimalAnimal study (in vivo)Safety outcome

    In ovariectomized monkeys, abaloparatide had no adverse effect on vertebral bone mass-strength relationships.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not harm the spinal bone mass-strength relationship compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeVertebral bone mass-strength relationship
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration was associated with greater lumbar vertebral strength, and had no adverse effects on bone mass-strength relationships for the vertebrae, femoral neck, femoral diaphysis, or humeral cortical beams.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  14. 14AnimalAnimal study (in vivo)Safety outcome

    In ovariectomized monkeys, abaloparatide had no adverse effect on femoral neck bone mass-strength relationships.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not harm the femoral neck bone mass-strength relationship compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral neck bone mass-strength relationship
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration was associated with greater lumbar vertebral strength, and had no adverse effects on bone mass-strength relationships for the vertebrae, femoral neck, femoral diaphysis, or humeral cortical beams.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  15. 15AnimalAnimal study (in vivo)Safety outcome

    In ovariectomized monkeys, abaloparatide had no adverse effect on femoral diaphysis bone mass-strength relationships.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not harm the femoral shaft bone mass-strength relationship compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeFemoral diaphysis bone mass-strength relationship
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration was associated with greater lumbar vertebral strength, and had no adverse effects on bone mass-strength relationships for the vertebrae, femoral neck, femoral diaphysis, or humeral cortical beams.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)
  16. 16AnimalAnimal study (in vivo)Safety outcome

    In ovariectomized monkeys, abaloparatide had no adverse effect on humeral cortical beam mass-strength relationships.

    In plain wordsIn monkeys with removed ovaries, abaloparatide did not harm the upper arm bone mass-strength relationship compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeHumeral cortical beam mass-strength relationship
    Study

    cynomolgus monkeyn: not reported in source

    Ovariectomized female cynomolgus monkeys
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.2, 1, or 5 μg/kg/day · subcutaneous · 16 monthsAs given in this study (cynomolgus monkey).

    Source sentences

    Summary
    Abaloparatide administration was associated with greater lumbar vertebral strength, and had no adverse effects on bone mass-strength relationships for the vertebrae, femoral neck, femoral diaphysis, or humeral cortical beams.
    2 context sentences
    Summary · context
    The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos).
    Summary · context
    After a 9-month period without treatments, OVX cynos were allocated to four groups that received 16 months of daily s.c. injections with either vehicle (n = 17) or abaloparatide (0.2, 1, or 5 μg/kg/day; n = 16/dose level)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.